Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2018
19th World Conference on Lung Cancer
Access to all presentations that occur during the 19th World Conference on Lung Cancer in Toronto, ON
Presentation Date(s):- Sept 23 - 26, 2018
- Total Presentations: 2384
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
P2.11 - Screening and Early Detection (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 29
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.11-01 - Blood Transcriptomics Enables Detection of Pre-Invasive & Minimally-Invasive Lung Adenocarcinoma
16:45 - 18:00 | Presenter: Baohui Han
- Abstract
Loading... -
+
P2.11-02 - Direct Comparison of New Solid Nodules Detected in Women and Men During Incidence Screening Rounds of the NELSON Trial
16:45 - 18:00 | Presenter: Joan E Walter
- Abstract
Loading... -
+
P2.11-03 - Cardiovascular Risk Prediction in a Community-Based Lung Cancer Screening Programme
16:45 - 18:00 | Presenter: Haval Balata
- Abstract
Loading... -
+
P2.11-04 - Treatment Capacity Required for Implementing Lung Cancer Screening in the United States
16:45 - 18:00 | Presenter: Erik Ferdinand Blom
- Abstract
Loading... -
+
P2.11-06 - A New Histoplasmosis Antibody Enzyme Immunoassay for the Diagnosis of Lung Benign Nodules
16:45 - 18:00 | Presenter: Stephen Deppen
- Abstract
Loading... -
+
P2.11-07 - Lung Cancer in a Tertiary Care Setting: So Near, Yet So Far
16:45 - 18:00 | Presenter: Kranti Garg
- Abstract
Loading... -
+
P2.11-08 - Tumor Autoantibody Panel Can Improve the Accuracy of Early Diagnosis in Lung Cancer Presenting with GGNs /Solid Nodules
16:45 - 18:00 | Presenter: Yayi He
- Abstract
Loading... -
+
P2.11-09 - Uncommon EGFR Mutation Analysis from Urine of Lung Cancer Patients
16:45 - 18:00 | Presenter: Prista Kusumaningtyas Hikmawati
- Abstract
Loading... -
+
P2.11-10 - Potential Utility of a Positive EarlyCDT®-Lung Blood Biomarker Test in Indeterminate Pulmonary Nodules
16:45 - 18:00 | Presenter: James Jett
- Abstract
Loading... -
+
P2.11-11 - Identification of the Genetic Determinants of Susceptibility to Lung Cancer in a Moroccan Cohort
16:45 - 18:00 | Presenter: Houda Kaanane
- Abstract
Loading... -
+
P2.11-12 - Metabolomic Analysis in Lung Cancer for Screening and Early Detection
16:45 - 18:00 | Presenter: Naohiro Kajiwara
- Abstract
Loading... -
+
P2.11-13 - Precise Early Detection of Lung Cancer and Blood Cell Circuit
16:45 - 18:00 | Presenter: Oleg Kshivets
- Abstract
Loading... -
+
P2.11-14 - Malignancy Associated Change and The LuCED® Test for Detection of Early Stage Lung Cancer
16:45 - 18:00 | Presenter: Michael Meyer
- Abstract
Loading... -
+
P2.11-15 - Identifying Patients for Whom Lung Cancer Screening is Preference-Sensitive: A Microsimulation Study
16:45 - 18:00 | Author(s): Tanner J Caverly
- Abstract
Loading... -
+
P2.11-16 - Comparison of Two Lung Cancer Screening Programs in One Medical Center - Does Experience of the Screening Team and Indications Affect the Results?
16:45 - 18:00 | Presenter: Marcin Ostrowski
- Abstract
Loading... -
+
P2.11-17 - MicroRNAs in Exhaled Breath Condensate and Bronchial Brushings as Biomarkers for Early Diagnosis of Lung Cancer
16:45 - 18:00 | Presenter: Bijay Pattnaik
- Abstract
Loading... -
+
P2.11-18 - A Comprehensive Lung Cancer Screening Program: 5 Years in Review
16:45 - 18:00 | Presenter: April Plank
- Abstract
Loading... -
+
P2.11-19 - MicroRNAs as Liquid Biopsy Biomarkers for Early Detection in Lung Cancer.
16:45 - 18:00 | Presenter: Patricia Reis
- Abstract
Loading... -
+
P2.11-20 - Lung EpiCheck TM - Results of the Training and Test Sets of a Methylation-Based Blood Test for Early Detection of Lung Cancer
16:45 - 18:00 | Presenter: Joanna Chorostowska-Wynimko
- Abstract
Loading... -
+
P2.11-21 - Factors Predicting Attrition in Community-Based Healthcare Network Lung Cancer Screening Programs
16:45 - 18:00 | Author(s): Kristin Mary Spiegel
- Abstract
Loading... -
+
P2.11-22 - Use of Electronic Medical Records for Tobacco Use and Lung Cancer Screening Documentation in a Large Urban Academic Medicine Practice
16:45 - 18:00 | Presenter: Giselle Alexandra Suero-Abreu
- Abstract
Loading... -
+
P2.11-23 - Risk Perception Among a Lung Cancer Screening Population
16:45 - 18:00 | Author(s): Jane Turner
- Abstract
Loading... -
+
P2.11-24 - Impact of Screening Interval Length on New Nodules Detected in Incidence Rounds of CT Lung Cancer Screening: the NELSON Trial
16:45 - 18:00 | Presenter: Joan E Walter
- Abstract
Loading... -
+
P2.11-25 - Lung Cancer Screening Implementation in Community Practice: Kaiser Permanente Washington Experience 2015-2018
16:45 - 18:00 | Presenter: Karen Wernli
- Abstract
Loading... -
+
P2.11-26 - First of its Kind Multi-Pronged Training for PCPs in an Epicenter of Lung Cancer – What Was Achieved in Two Years?
16:45 - 18:00 | Presenter: Celeste T. Worth
- Abstract
Loading... -
+
P2.11-27 - A Rapid Access Lung Cancer Clinic Reduces Variation in Lung Cancer Diagnostic and Treatment Services.
16:45 - 18:00 | Author(s): Thabisa Sibanda
- Abstract
Loading... -
+
P2.11-28 - A Focus Group and Interview Study to Explore the Information-Needs of Lung Cancer Screening Participants
16:45 - 18:00 | Presenter: Mamta Ruparel
- Abstract
Loading... -
+
P2.11-29 - Impact of an Information-Film to Promote Informed Decision-Making in Individuals Taking Part in a Lung Cancer Screening Demonstration Pilot
16:45 - 18:00 | Presenter: Mamta Ruparel
- Abstract
Loading... -
+
P2.11-29a - Modified Lung-RADS Improves Performance of Screening LDCT in a Population with High Prevalence of Non–Smoking-Related Lung Cancer
16:45 - 18:00 | Author(s): FU ZONG Wu
- Abstract
Loading...
-
+
P2.12 - Small Cell Lung Cancer/NET (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 18
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.12-01 - Efficacy of Belotecan as Second-Line Treatment for Recurrent Small Cell Lung Cancer: A Phase IIb Randomized Multicenter Study
16:45 - 18:00 | Presenter: Jin-Hyoung Kang
- Abstract
Loading... -
+
P2.12-02 - Phase II Study of Combination of Nab-Paclitaxel and Gemcitabine for Relapsed Small Cell Lung Cancer (SCLC)
16:45 - 18:00 | Presenter: Muhammad Furqan
- Abstract
Loading... -
+
P2.12-03 - Phase I/II Trial Of 177Lu-DOTA0-Tyr3-Octreotate (Lutathera) And Nivolumab for Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
16:45 - 18:00 | Presenter: Chul Kim
- Abstract
Loading... -
+
P2.12-04 - Liposomal Irinotecan vs Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed On/After Platinum-Based Therapy
16:45 - 18:00 | Author(s): Luis Paz-Ares
- Abstract
Loading... -
+
P2.12-05 - SUKSES (Small Cell Lung Cancer Umbrella Korea Studies): A Phase II Biomarker-Driven Umbrella Study in Relapsed or Refractory SCLC
16:45 - 18:00 | Author(s): Sehhoon Park
- Abstract
Loading... -
+
P2.12-06 - The Efficacy of Apatinib Plus Topotecan as Laterline Therapy for Advanced Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Haifeng Qin
- Abstract
Loading... -
+
P2.12-07 - Utility of Stereotactic Body Radiotherapy in Pulmonary Carcinoid Tumors
16:45 - 18:00 | Presenter: Robert A Ramirez
- Abstract
Loading... -
+
P2.12-08 - Network Meta-Analysis of Angiogenesis Inhibitors on Survival of Patients with Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Xiaoshun Shi
- Abstract
Loading... -
+
P2.12-09 - Efficacy and Safety of Carboplatin and Paclitaxel for Patients Preexisting Interstitial Lung Disease with Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Ayumi Uchiyama
- Abstract
Loading... -
+
P2.12-10 - Novel Prognostic Model for Limited-Stage Small-Cell Lung Cancer
16:45 - 18:00 | Presenter: Hanbo Chen
- Abstract
Loading... -
+
P2.12-11 - A Prognostic Model Integrating Immunohistochemistry Markers for Extensive-Disease Small-Cell Lung Cancer
16:45 - 18:00 | Presenter: Rui Fu
- Abstract
Loading... -
+
P2.12-12 - Plasma Vitamin D Level is an Independent Prognosis Factor in SCLC Patients Treated with Platinum Plus Etoposide as First-Line Chemotherapy
16:45 - 18:00 | Presenter: Xu Wang
- Abstract
Loading... -
+
P2.12-13 - Effectiveness of Hypofractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Propensity Score Analysis
16:45 - 18:00 | Presenter: Hanbo Chen
- Abstract
Loading... -
+
P2.12-14 - Stereotactic Radiosurgery for Brain Metastases in Small Cell Lung Cancer.
16:45 - 18:00 | Presenter: Elizabeth Dudnik
- Abstract
Loading... -
+
P2.12-15 - Prognostic and Predictive Covariates in Limited-Stage Small-Cell Lung Cancer: Analysis of the Phase 3 CONVERT Trial
16:45 - 18:00 | Author(s): Ahmed Salem
- Abstract
Loading... -
+
P2.12-16 - Significant Tumor Regression and Toxicity with Nivolumab Plus Ipilimumab in Small Cell Lung Cancer Patients Following Radiation
16:45 - 18:00 | Presenter: Brendan Gilmore
- Abstract
Loading... -
+
P2.12-17 - Prophylactic Cranial Irradiation Can Not Provide Survival Benefits for Resected Small Cell Lung Cancer Without Lymph Node Involvement
16:45 - 18:00 | Presenter: Baohui Han
- Abstract
Loading... -
+
P2.12-18 - Interstitial Lung Abnormalities are a Risk Factor for Radiation Pneumonitis in Patients with Limited-Stage Small-Cell Lung Cancer
16:45 - 18:00 | Presenter: Fangjuan Li
- Abstract
Loading...
-
+
P2.13 - Targeted Therapy (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 45
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.13-01 - Brigatinib Use in England – Where Next?
16:45 - 18:00 | Presenter: Fabio Gomes
- Abstract
Loading... -
+
P2.13-02 - ALK-Translocation and Brain Metastases: A Retrospective Study. Correlation Between Clinical Outcome, Disease Burden and Management.
16:45 - 18:00 | Presenter: Oscar Grundberg
- Abstract
Loading... -
+
P2.13-03 - Real-Life Experience with Brigatinib in Pretreated EML4-ALK Translocated NSCLC Patients
16:45 - 18:00 | Presenter: Maximilian Johannes Hochmair
- Abstract
Loading... -
+
P2.13-04 - Outcomes of ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Crizotinib: A Multicenter Cohort Retrospective Study.
16:45 - 18:00 | Author(s): Puyuan Xing
- Abstract
Loading... -
+
P2.13-05 - Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients with Advanced ALK-Positive NSCLC.
16:45 - 18:00 | Presenter: Di Ma
- Abstract
Loading... -
+
P2.13-06 - TP53 Status in Relation to Response to Anti-ALK Agents in Patients with EML4-ALK-Translocated NSCLC
16:45 - 18:00 | Author(s): Matteo Canale
- Abstract
Loading... -
+
P2.13-07 - CUX1-ALK: A Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer
16:45 - 18:00 | Author(s): Meiling Zhang
- Abstract
Loading... -
+
P2.13-09 - Efficacy and Safety of Osimertinib After Prior EGFR TKI: Analysis of Patients Underrepresented in Randomized Clinical Trials
16:45 - 18:00 | Presenter: Luiz H. Araujo
- Abstract
Loading... -
+
P2.13-10 - Ph I/II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Erlotinib in pts with EGFRm NSCLC
16:45 - 18:00 | Presenter: Lauren Byers
- Abstract
Loading... -
+
P2.13-11 - EGFR Amplification and Sensitizing Mutations Correlates with Survival from Erlotinib in Lung Adenocarcinoma Patients (MutP-CLICAP¶)
16:45 - 18:00 | Presenter: Andrés F. Cardona
- Abstract
Loading... -
+
P2.13-12 - The deNovo T790M Mutation Recovered by ddPCR is Associated with a Poor Response to 1st and 2nd Generation EGFR-TKI in Lung Adenocarcinoma.
16:45 - 18:00 | Author(s): Eun Young Kim
- Abstract
Loading... -
+
P2.13-13 - Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis
16:45 - 18:00 | Presenter: Parneet Kaur Cheema
- Abstract
Loading... -
+
P2.13-14 - The Clinical Usefulness of Liquid Biopsy for Detection and Dynamic Monitoring of EGFR T790M in NSCLC Patients on EGFR-TKI Therapy
16:45 - 18:00 | Author(s): Adam Szpechcinski
- Abstract
Loading... -
+
P2.13-15 - Short-Term Responders of NSCLC to EGFR-TKIs Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms
16:45 - 18:00 | Author(s): Yanjun Xu
- Abstract
Loading... -
+
P2.13-16 - Preference of Adjuvant Treatments for EGFR-Mutant Resected NSCLC Patients: Results of a National-Wide Survey in China
16:45 - 18:00 | Author(s): Minzhang Guo
- Abstract
Loading... -
+
P2.13-17 - Non-Small Cell Lung Cancer in the Very Young: More EGFR/ALK Mutation Rate Than the Elder
16:45 - 18:00 | Presenter: ChienHui He
- Abstract
Loading... -
+
P2.13-18 - A Multicenter Prospective Biomarker Study to Explore Mechanisms of Afatinib Resistance Based on Digita PCR and Next-Generation Sequencing
16:45 - 18:00 | Presenter: Eiji Iwama
- Abstract
Loading... -
+
P2.13-19 - Prognostic Value Inferred from the Quantitative Measurement of EGFR Mutation Using PNA-Clamping Method in Advanced EGFR Mutant NSCLC Patients
16:45 - 18:00 | Presenter: Mi-hyun Kim
- Abstract
Loading... -
+
P2.13-20 - The Comparative Effectiveness of Gefitinib Versus Erlotinib on the Intracranial Progression-Free Survival in Patients with Brain Metastasis
16:45 - 18:00 | Presenter: Yao-Wen Kuo
- Abstract
Loading... -
+
P2.13-21 - MET Addiction Can be Circumvented Through EGFR Inhibition Via AXL in MET-Amplified Primary Resistant EGFR-Mutant NSCLC
16:45 - 18:00 | Presenter: Xue Lin Kwang
- Abstract
Loading... -
+
P2.13-22 - Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation
16:45 - 18:00 | Presenter: Jae Cheol Lee
- Abstract
Loading... -
+
P2.13-23 - Osimertinib Treatment Result of Plasma T790M Positive in Different Clinical Failure Modes After First-Line EGFR TKI for EGFR Mutant NSCLC
16:45 - 18:00 | Presenter: Haiyan Li
- Abstract
Loading... -
+
P2.13-24 - Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790M-Mutant NSCLC Patients
16:45 - 18:00 | Presenter: Jordi Remon
- Abstract
Loading... -
+
P2.13-25 - Analysis of EGFR Mutations Using Circulating Tumour DNA (ctDNA) in Non-Small Cell Lung Cancer Patients in North East Scotland
16:45 - 18:00 | Presenter: Paula Scott
- Abstract
Loading... -
+
P2.13-26 - Impact of Concurrent Tumor Suppressor Gene Mutation on Clinical Outcomes in EGFR Mutated NSCLC Treated with First-Line TKI
16:45 - 18:00 | Presenter: Sandhya Sharma
- Abstract
Loading... -
+
P2.13-27 - Development, Internal Validation, and Calibration of a Risk Score to Predict Survival in Patients with EGFR Mutant NSCLC
16:45 - 18:00 | Author(s): Isaac Kah Siang Ng
- Abstract
Loading... -
+
P2.13-28 - Comparison of ddPCR and NGS in Liquid Biopsy to Pathology Results in EGFR-Mutated NSCLC
16:45 - 18:00 | Presenter: Christi Marja Johanna Steendam
- Abstract
Loading... -
+
P2.13-29 - IL-22 Confers Resistance To EGFR-TKIs In Non-Small Cell Lung Cancer Bearing EGFR Gene Mutation and Amplification
16:45 - 18:00 | Author(s): Xiaomeng Wang
- Abstract
Loading... -
+
P2.13-30 - High-Dose Icotinib in Advanced Non-Small Cell Lung Cancer with EGFR 21 L858R Mutation: The Randomized, Open-Label INCREASE Study
16:45 - 18:00 | Author(s): Xi Li
- Abstract
Loading... -
+
P2.13-31 - p.(Leu747Pro) Mutation Leads to Misdiagnosis in EGFR Mutation Assessment – Analysis in a Cohort of 1841 Polish NSCLC Patients
16:45 - 18:00 | Author(s): Katarzyna Duk
- Abstract
Loading... -
+
P2.13-32 - TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2
16:45 - 18:00 | Presenter: Jouhara Chouitar
- Abstract
Loading... -
+
P2.13-33 - A Case Report of Exceptional Clinical Response to MEK Inhibition in a Patient with NRAS Mutation Positive NSCLC
16:45 - 18:00 | Author(s): Matthew G Krebs
- Abstract
Loading... -
+
P2.13-34 - Long Intergenic Non-Coding RNA 00665 Induces Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer
16:45 - 18:00 | Author(s): Xinyin Liu
- Abstract
Loading... -
+
P2.13-35 - Inhibition of H3K27 Demethylation is Toxic in Poorly Differentiated Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Timothy L Lochmann
- Abstract
Loading... -
+
P2.13-36 - Analysis of CDK4/6 Pathway Activity in Lung Adenocarcinoma Patients with Oncogenic Driver Mutations in China
16:45 - 18:00 | Author(s): Yongfeng Yu
- Abstract
Loading... -
+
P2.13-37 - Chloroquine overcomes acquired resistance to icotinib in vitro and in vivo through STAT3/STMN1 pathway
16:45 - 18:00 | Presenter: Xin Lyu
- Abstract
Loading... -
+
P2.13-38 - Impact of Tyrosine Kinase Inhibitor (TKI) Dose on Outcomes of Patients with Lung Cancer
16:45 - 18:00 | Presenter: Emily Miao
- Abstract
Loading... -
+
P2.13-39 - A Phase Ib Trial of the HSP90 Inhibitor AUY922 in Combination with Pemetrexed in Metastatic Non-Squamous, Non-Small Cell Lung Cancer Patients
16:45 - 18:00 | Presenter: Zorawar Noor
- Abstract
Loading... -
+
P2.13-40 - ABP 215 and Bevacizumab in NSCLC Patients: Time Course and Magnitude of Response in the Phase 3 Comparative Trial (MAPLE)
16:45 - 18:00 | Author(s): Nick Thatcher
- Abstract
Loading... -
+
P2.13-41 - A Novel Mitochondria-Based Targeting to Restore Therapeutic Response in Cisplatin- and Gefitinib-Resistant Human Lung Cancer Cells
16:45 - 18:00 | Presenter: Qinghua Zhou
- Abstract
Loading... -
+
P2.13-42 - Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer
16:45 - 18:00 | Author(s): Bianca Van Veggel
- Abstract
Loading... -
+
P2.13-43 - Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC
16:45 - 18:00 | Presenter: Pasi A Jänne
- Abstract
Loading... -
+
P2.13-44 - Targeting NFE2L2 Mutations in Advanced Squamous Cell Lung Cancers with the TORC1/2 Inhibitor TAK-228
16:45 - 18:00 | Presenter: Paul K. Paik
- Abstract
Loading... -
+
P2.13-45 - SHERLOC: A Phase 2 Study of Seribantumab in Combination with Docetaxel in Patients with Heregulin Positive, Advanced NSCLC
16:45 - 18:00 | Presenter: Lecia Sequist
- Abstract
Loading... -
+
P2.13-46 - Comprehensive Investigation of ERBB2 Transmembrane Domain Mutations (V659/G660) in 12,833 Chinese Lung Cancer Patients
16:45 - 18:00 | Author(s): Ruoying Yu
- Abstract
Loading...
-
+
P2.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 33
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.15-01 - CANscript™ as a Patient-Derived Predictive Platform for individualizing Treatment in Lung Cancer
16:45 - 18:00 | Presenter: K Govind Babu
- Abstract
Loading... -
+
P2.15-02 - Gender-Associated Differences in Patients with Lung Cancer Treated at an Argentinean University Hospital in the Last 10 Years
16:45 - 18:00 | Presenter: Carolina Gabay
- Abstract
Loading... -
+
P2.15-03 - Availability and Reimbursement of Diagnostic Testing and Novel Anti-Cancer Drugs for NSCLC in CEE: Results of a CECOG Survey
16:45 - 18:00 | Presenter: Luka Brcic
- Abstract
Loading... -
+
P2.15-04 - Costs of Cares on the Month Before Death of Patients with Lung Cancer: A French National Database Survey
16:45 - 18:00 | Presenter: Olivier Bylicki
- Abstract
Loading... -
+
P2.15-05 - Prescribing Patterns of Physicians and Financial Implications for Lung Cancer Treatment at the End of Life
16:45 - 18:00 | Author(s): Tsz Chan
- Abstract
Loading... -
+
P2.15-06 - Examination of Optimal Timing of Post-Surgical Surveillance for Early Stage Lung Cancer Patients and Association with Outcomes
16:45 - 18:00 | Author(s): Elizabeth Colwell
- Abstract
Loading... -
+
P2.15-07 - Lung Cancer in the Young
16:45 - 18:00 | Presenter: Marco Galvez Nino
- Abstract
Loading... -
+
P2.15-08 - Impact and Feasibility of a Support Group for Women with Lung Cancer
16:45 - 18:00 | Author(s): Joanna Gotfrit
- Abstract
Loading... -
+
P2.15-09 - The Impact of Treatment Evolution in NSCLC (iTEN) Model: Survival and Cost of Treating Patients with Advanced NSCLC in 2017
16:45 - 18:00 | Presenter: Daniel Moldaver
- Abstract
Loading... -
+
P2.15-10 - Determinants of Health Utility Scores (HUS) in Patients with ALK Rearranged Non-Small Cell Lung Cancer.
16:45 - 18:00 | Presenter: Badr Id Said
- Abstract
Loading... -
+
P2.15-11 - Clinical Outcome of Pulmonary Resection for Non–Small Cell Lung Cancer in Extremely Elderly Patients (85-Year-Old or Over)
16:45 - 18:00 | Presenter: Hiroaki Inoue
- Abstract
Loading... -
+
P2.15-12 - Exparel vs. Bupivicaine for Postoperative Analgesia After VATS Lung Resection: Results of a Randomized Control Trial
16:45 - 18:00 | Presenter: Sandeep Khandhar
- Abstract
Loading... -
+
P2.15-13 - Implementation of a Democratized Approach to Multi-Omic Molecular Profiling Via the LungMATCH Program.
16:45 - 18:00 | Presenter: Jennifer C King
- Abstract
Loading... -
+
P2.15-14 - Survivorship of Advanced Lung Cancer Patients with Psychiatric Disorders and Malnutrition Risk
16:45 - 18:00 | Presenter: Tomi Kovacevic
- Abstract
Loading... -
+
P2.15-15 - Differentiating Characteristics of Patients Seeking a Second Opinion: A Survey on Non-Small Cell Lung Cancer Patients
16:45 - 18:00 | Author(s): Kathryn Volpicelli Leonard
- Abstract
Loading... -
+
P2.15-16 - Clinical Economic Impact of Improved Genotyping in Patients with Advanced Non-Small Cell Lung Adenocarcinoma (NSCLC)
16:45 - 18:00 | Author(s): Gilberto de Lima Lopes
- Abstract
Loading... -
+
P2.15-17 - Patient Care in Advanced Lung Cancer: Unmet Needs
16:45 - 18:00 | Presenter: Jean-François Morere
- Abstract
Loading... -
+
P2.15-18 - Cost-Effectiveness Analysis of Second-Line Immune Checkpoint Inhibitors for Advanced NSCLC in Colombia
16:45 - 18:00 | Presenter: Aylen Vanessa Ospina Serrano
- Abstract
Loading... -
+
P2.15-19 - Inequality of Access to Novel Lung Cancer Therapies in Europe
16:45 - 18:00 | Presenter: Hazel O'Sullivan
- Abstract
Loading... -
+
P2.15-20 - Educating The Multispecialty Team on Molecular Testing Related to Immunotherapy
16:45 - 18:00 | Author(s): Tara Perloff
- Abstract
Loading... -
+
P2.15-21 - Post Resection Lung Cancer Surveillance: Comparisons of Practice Between STS, ESTS and JACS Members
16:45 - 18:00 | Presenter: Cecilia Pompili
- Abstract
Loading... -
+
P2.15-22 - Optimal Glycemic Control Improves Prognosis for Lung Cancer Patients with Diabetes Mellitus
16:45 - 18:00 | Author(s): Jie Qian
- Abstract
Loading... -
+
P2.15-23 - Are there Ethnic Disparities in the Clinical Outcomes of Non-Small Cell Lung Cancer Hispanic Patients Treated with Immunotherapy?
16:45 - 18:00 | Presenter: Luis E Raez
- Abstract
Loading... -
+
P2.15-24 - Comparison of Pemetrexed Administered q 3 Weeks vs q 4 Weeks as Maintenance Therapy in NSCLC: Analysis of Real World Data from a Single Institution
16:45 - 18:00 | Author(s): Grace K Dy
- Abstract
Loading... -
+
P2.15-25 - NIVEX TRIAL (GECP 1605): Nivolumab in the Real World: Spanish Expanded Access Program Experience in Pretreated Advanced NSCLC Patients
16:45 - 18:00 | Presenter: Delvys Rodríguez-Abreu
- Abstract
Loading... -
+
P2.15-26 - Rates and Economic Burden of Adverse Events in Patients With Metastatic NSCLC Treated with EGFR-TKIs
16:45 - 18:00 | Presenter: Janakiraman Subramanian
- Abstract
Loading... -
+
P2.15-27 - Lung Volume Change After Lobectomy Estimated by Three-Dimensional Image Analysis System
16:45 - 18:00 | Presenter: Hirofumi Suzuki
- Abstract
Loading... -
+
P2.15-28 - Effect of Insurance Types on Tumor Recurrence and Overall Survival in Resectable Non-Small Lung Cancer Patients in Northern Thailand
16:45 - 18:00 | Author(s): Apichat Tantraworasin
- Abstract
Loading... -
+
P2.15-29 - Eligibility for Anti-Angiogenic Treatments in Patients with Squamous Non-Small Cell Lung Cancer (SQ-NSCLC): EPISQUAMAB Study (GFPC 2015-01)
16:45 - 18:00 | Presenter: Alain Vergnenegre
- Abstract
Loading... -
+
P2.15-30 - Marital Status and Survival in Patients with Lung Cancer
16:45 - 18:00 | Presenter: Buhai Wang
- Abstract
Loading... -
+
P2.15-31 - The Evolution of Costs in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada Between 1999 to 2014
16:45 - 18:00 | Presenter: Ying Wang
- Abstract
Loading... -
+
P2.15-32 - Novice Training : The Time Course for Developing Competence in Single Port Video-Assisted Thoracoscopic Lobectomy
16:45 - 18:00 | Presenter: Ching Feng Wu
- Abstract
Loading... -
+
P2.15-33 - Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced NSCLC: What Happens After Panel Testing by NGS?
16:45 - 18:00 | Author(s): Jing Zhao
- Abstract
Loading...
-
+
P2.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 51
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.16-01 - Prognostic Significance of Preoperative Consolidation to Maximum Tumor Diameter Ratio and Suv-Max in Pathological Stage I Lung Adenocarcinoma
16:45 - 18:00 | Presenter: Pınar Akın Kabalak
- Abstract
Loading... -
+
P2.16-02 - Predicting Pathological Noninvasiveness in T1 Non-Small Cell Lung Cancer on Chest CT Scan Using Deep Learning Algorithm
16:45 - 18:00 | Presenter: Kyongmin Sarah Beck
- Abstract
Loading... -
+
P2.16-03 - CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC
16:45 - 18:00 | Presenter: Enriqueta Felip
- Abstract
Loading... -
+
P2.16-04 - Prognostic Value of Lymphovascular Invasion and Its Effect on Patterns of Recurrence in T1-3N0 Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Yeon Sil Kim
- Abstract
Loading... -
+
P2.16-05 - Hypermethylation of SOX1, RASSF1A, HOXA9, CDH13 and DAPK Genes Plays a Role in NSCLC Pathogenesis
16:45 - 18:00 | Presenter: Milica Kontic
- Abstract
Loading... -
+
P2.16-06 - Development and Validation of a Gene Expression-Based Nomogram to Predict Relapse in Stage I NSCLC: A Retrospective, Multi-Cohort Study
16:45 - 18:00 | Presenter: Qixing Mao
- Abstract
Loading... -
+
P2.16-07 - Impact of de Novo T790M on Outcome for Resected NSCLC from EGFR Mutant Cohort of Japan Molecular Epidemiology (JME) Study
16:45 - 18:00 | Presenter: Yoshiya Matsumoto
- Abstract
Loading... -
+
P2.16-08 - Influence of Tumour Location and Histological Sub-Type of Non-Small Cell Lung Cancer on Patient Survival
16:45 - 18:00 | Presenter: Alan McWilliam
- Abstract
Loading... -
+
P2.16-09 - Patterns of Brain Metastases in Stage I-III Non-Small Cell Lung Cancer: An NCDB Analysis
16:45 - 18:00 | Presenter: Stephanie Renee Rice
- Abstract
Loading... -
+
P2.16-10 - Prognostic Impact of Postoperative C-Reactive Protein for Non-Small Cell Lung Cancer Following Lobectomy
16:45 - 18:00 | Presenter: Shuichi Shinohara
- Abstract
Loading... -
+
P2.16-11 - Prognostic Role of Combined Pulmonary Fibrosis and Emphysema (CPFE) in Patients with Clinical Stage I Lung Cancer.
16:45 - 18:00 | Presenter: Yasuhiro Tsutani
- Abstract
Loading... -
+
P2.16-12 - Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy
16:45 - 18:00 | Presenter: Gavitt A. Woodard
- Abstract
Loading... -
+
P2.16-13 - A Proposal of Classification for Subsolid Nodule: Prognostic Impact of T Descriptor
16:45 - 18:00 | Presenter: Erjia Zhu
- Abstract
Loading... -
+
P2.16-14 - Results of Stereotactic Radiation Therapy (SABR) in Early Stage Lung Cancer: Turkish Radiation Oncology Group (TROG) Study
16:45 - 18:00 | Presenter: Banu Atalar
- Abstract
Loading... -
+
P2.16-15 - Toxicities and Survival after Stereotactic Ablative Radiotherapy (SABR) for Centrally Located Lung Tumors
16:45 - 18:00 | Presenter: Banu Atalar
- Abstract
Loading... -
+
P2.16-16 - SABRTOOTH: A Fasibility Study of SABR Versus Surgery in Patients with Peripheral Stage I NSCLC Considered to be at Higher Risk for Surgery.
16:45 - 18:00 | Presenter: Kevin Franks
- Abstract
Loading... -
+
P2.16-17 - Hypo-Fractionated Accelerated Radiotherapy in Central Early Non-Small Cell Lung Cancer: Leeds Cancer Centre Experience.
16:45 - 18:00 | Author(s): TANZEEL Janjua
- Abstract
Loading... -
+
P2.16-18 - Study of Interstitial Lung Disease and Acute Exacerbation in Patients Receiving Radiation Therapy for Lung Cancer in Japan.
16:45 - 18:00 | Presenter: Yasuhito Hagiwara
- Abstract
Loading... -
+
P2.16-19 - Feasibility and Outcomes of Radiofrequency Ablation as Salvage Modality After Hypofractionated Radiation/SBRT for Early NSCLC
16:45 - 18:00 | Presenter: Ritika Harjani Hinduja
- Abstract
Loading... -
+
P2.16-20 - Prognostic Utility of PET in Non-Small Cell Lung Cancer After Empiric Stereotactic Body Radiotherapy (SBRT)
16:45 - 18:00 | Presenter: Shaakir Hasan
- Abstract
Loading... -
+
P2.16-21 - Post-Treatment Survival Difference Between Lobectomy and Stereotactic Ablative Radiotherapy in Stage 1 Non-Small Cell Lung Cancer in England
16:45 - 18:00 | Author(s): Aamir Khakwani
- Abstract
Loading... -
+
P2.16-22 - Comparing Two Common Radiotherapy Regimens in Non-Small Cell Lung Cancer - A Retrospective Study
16:45 - 18:00 | Author(s): Wai-Yan Poon
- Abstract
Loading... -
+
P2.16-23 - Focal Therapy for Small Lung Cancer with Ethanol Release Heat-Generating Polymer
16:45 - 18:00 | Presenter: Junichi Shimada
- Abstract
Loading... -
+
P2.16-24 - Racial Differences in Treatment and Survival of Stage I NSCLC: A Comparison of Veterans Affairs (VA) and SEER-Medicare Populations
16:45 - 18:00 | Presenter: Christina D Williams
- Abstract
Loading... -
+
P2.16-25 - Lower Hiliar Lymph Node Upstaging in Early NSCLC Vats Surgery is Related to Tumor Location and Does Not Afect Survival
16:45 - 18:00 | Presenter: Marc Boada
- Abstract
Loading... -
+
P2.16-26 - Lung Cancer Resection in Patients with Criteria for Lung Cancer Screening Provides Satisfactory Short Term Results
16:45 - 18:00 | Presenter: David Boulate
- Abstract
Loading... -
+
P2.16-27 - Indocyanine Green Virtual Assisted Lung Mapping (ICG-VAL-MAP): Anyone Can Perform a Visible Preoperative Marking Successfully
16:45 - 18:00 | Presenter: Toyofumi Fengshi Chen-Yoshikawa
- Abstract
Loading... -
+
P2.16-28 - Comparison of Outcomes of VATS Segmentectomy Versus Lobectomy for Non-Small Cell Lung Cancer Using a Propensity Score Matching Analysis
16:45 - 18:00 | Presenter: Yoohwa Hwang
- Abstract
Loading... -
+
P2.16-29 - Clinical Outcomes of Surgically Resected Extraabdominal Chest Wall Desmoid Tumors
16:45 - 18:00 | Presenter: Seok Kim
- Abstract
Loading... -
+
P2.16-30 - Surgical Strategy for Clinical Stage IA Non-Small Cell Lung Cancer Patients with Risk Factors of Pathological Invasion and/or Metastasis
16:45 - 18:00 | Presenter: Terumoto Koike
- Abstract
Loading... -
+
P2.16-31 - Examination of the Intersegmental Isolation Method in the Segmental Resection Considering Respiratory Function Preservation
16:45 - 18:00 | Presenter: Katsuo Kojima
- Abstract
Loading... -
+
P2.16-32 - Survival Implications and Factors Associated with the Anatomic Level of Incomplete Non-Small-Cell Lung Cancer (NSCLC) Resection
16:45 - 18:00 | Presenter: Yu-Sheng Lee
- Abstract
Loading... -
+
P2.16-33 - Adenosquamous Carcinoma of the Lung: Comparison of Surgical Outcomes with Squamous Cell and Adenocarcinoma
16:45 - 18:00 | Presenter: Huseyin Melek
- Abstract
Loading... -
+
P2.16-34 - Visceral Pleural Invasion is Closely Associated with Nodal Spread in cStage IA Lung Adenocarcinoma
16:45 - 18:00 | Presenter: Tetsuya Mizuno
- Abstract
Loading... -
+
P2.16-35 - Analysis of Pre and Intra Operative Factors Related to the Operation Time of Lobectomy in VATS: Is the Shape of Thoracic Cavity a Predictive Factor?
16:45 - 18:00 | Presenter: Takuya Nagashima
- Abstract
Loading... -
+
P2.16-36 - Adjuvant Chemotherapy is Effective for Completely Resected Stage IB Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Masao Nakata
- Abstract
Loading... -
+
P2.16-37 - The Introduction of Robotic Lobectomy for Non-Small Cell Lung Cancer in South East Asia: A 5-Year Single Centre Study
16:45 - 18:00 | Presenter: Kingsfield Ong
- Abstract
Loading... -
+
P2.16-38 - Characteristics of Preoperative N Staging in Patients with Optimal Pathologic N Staging of Non Small Cell Lung Cancer(NSCLC)
16:45 - 18:00 | Presenter: Meredith A Ray
- Abstract
Loading... -
+
P2.16-39 - The Application of 3D Medical Image Analyzer and a Fluorescence Guided Surgery for Pulmonary Sublobar Resection
16:45 - 18:00 | Presenter: Yasuo Sekine
- Abstract
Loading... -
+
P2.16-40 - Impact of Preoperative Pectoralis Muscle Quantity and Density on Outcome After Complete Resection of Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Changbo Sun
- Abstract
Loading... -
+
P2.16-41 - Intraoperative Computed Tomography After Tumor Marking with Metal Clips for Non-Palpable Lung Tumors
16:45 - 18:00 | Presenter: Yoshimasa Tokunaga
- Abstract
Loading... -
+
P2.16-42 - Standard Mediastinoscopy Versus Video-Assisted Mediastinoscopic Lymphadectomy in Clinical N1 Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Akif Turna
- Abstract
Loading... -
+
P2.16-43 - Diabetes is a Negative Prognostic Factor in Non-Small Cell Lung Cancer Patients Undergoing Resectional Surgery
16:45 - 18:00 | Author(s): Irem Yasar
- Abstract
Loading... -
+
P2.16-44 - Long-Term Outcome of Pulmonary Segmentectomy for c-IA Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Hironobu Wada
- Abstract
Loading... -
+
P2.16-45 - Should Patients with Stage IB Non-Small Cell Lung Cancer Receive Adjuvant Chemotherapy?
16:45 - 18:00 | Presenter: Jia Wang
- Abstract
Loading... -
+
P2.16-46 - Clinical Outcomes and Treatment Strategies of Sarcomatoid Carcinoma of the Lung
16:45 - 18:00 | Presenter: Yan Wang
- Abstract
Loading... -
+
P2.16-47 - “Improved aBVA Method” and “Anterior VAB Method” Result in Analogous Survival Benefits During Right Upper Lobectomy
16:45 - 18:00 | Presenter: Jin Xia
- Abstract
Loading... -
+
P2.16-48 - Outcomes of Stage I Lung Cancer Patients Treated with Segmentectomy via Three-Dimensional Uniportal VATS Versus Two-Dimensional Approach
16:45 - 18:00 | Presenter: Chengliang Yang
- Abstract
Loading... -
+
P2.16-49 - Which Nomogram is More Reliable to Predict Recurrence of Pathological Stage IA Lung Adenocarcinoma Treated by Surgery?
16:45 - 18:00 | Presenter: Lu Yang
- Abstract
Loading... -
+
P2.16-50 - Do Patients Have Preconceived Ideas on Various Surgical Approaches? Patient Perspective: Open vs. Minimally Invasive Surgery (PROMIS) Survey.
16:45 - 18:00 | Presenter: Ching Yeung
- Abstract
Loading... -
+
P2.16-51 - Nationwide Trends in Surgical Treatment of Lung Cancer in Estonia, 2000−2015
16:45 - 18:00 | Presenter: Tanel Laisaar
- Abstract
Loading...
-
+
P2.17 - Treatment of Locoregional Disease - NSCLC (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 33
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.17-01 - Trimodality Therapy (TT) in the Treatment of Stage IIIA Non-Small Cell Lung Cancer (NSCLC)
16:45 - 18:00 | Presenter: Tahir Mehmood
- Abstract
Loading... -
+
P2.17-02 - Cardiopulmonary Exercise Tests in Lung Cancer Patients Treated Radical Radiotherapy and Chemotherapy – Feasibility Study
16:45 - 18:00 | Presenter: Nazia Mohammed
- Abstract
Loading... -
+
P2.17-03 - A Propensity-Matched Analysis of Neoadjuvant Chemoradiotherapy and Adjuvant Chemoradiotherapy for IIIA(N2) Non-Small Cell Lung Cancer
16:45 - 18:00 | Author(s): Yaoyao Zhu
- Abstract
Loading... -
+
P2.17-04 - Imiquimod Attenuates Radiation-Induced Pulmonary Fibrosis
16:45 - 18:00 | Author(s): Mustafa Calik
- Abstract
Loading... -
+
P2.17-05 - Consolidation Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer After Concurrent Chemoradiotherapy
16:45 - 18:00 | Presenter: Fatma Basal
- Abstract
Loading... -
+
P2.17-06 - Functional Lung Imaging in Radiotherapy for Lung Cancer: A Systematic Review and Meta-Analysis
16:45 - 18:00 | Presenter: Nicholas Wentworth Bucknell
- Abstract
Loading... -
+
P2.17-07 - Concurrent Chemoradiotherapy (ConCRT) using Cisplatin-Vinorelbine in Locally Advanced (LA) Non-Small Cell Lung Cancer (NSCLC)
16:45 - 18:00 | Presenter: Haris Charalambous
- Abstract
Loading... -
+
P2.17-08 - Heart Motion in Lung Radiotherapy: How Representative Are Delineations Based on 3DCT, Average and Maximum Projection Scans?
16:45 - 18:00 | Author(s): Eliana Vasquez Osorio
- Abstract
Loading... -
+
P2.17-09 - Exploring the Impact of Age on the Efficacy of Adjuvant Chemotherapy After Radical Resection in Non- Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Catherine Joan Davidson
- Abstract
Loading... -
+
P2.17-10 - Daily Low–Dose Cisplatin and High Dose Radiotherapy for Elderly Patients with Stage III NSCLC is Well Tolerated.
16:45 - 18:00 | Presenter: E.M.T. Dieleman
- Abstract
Loading... -
+
P2.17-11 - Impact of Quantitatively Assessed Emphysema on Chest Tube Drainage After Lobectomy for Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Tomasz Gil
- Abstract
Loading... -
+
P2.17-12 - Eliminating Radiation Resistance of Non-Small Cell Lung Cancer By DHA Trough Abrogating Immunity Escaping via Inhibiting PD-L1 Expression
16:45 - 18:00 | Presenter: Xiaomei Gong
- Abstract
Loading... -
+
P2.17-13 - Genome-Wide Copy Number Alterations Profiling Predict Efficacy of Resected Stage II-IIIA Lung Adenocarcinoma
16:45 - 18:00 | Presenter: Xiaohong Han
- Abstract
Loading... -
+
P2.17-14 - How Should Positive Margin for Bronchial Stumps (R1) Be Evaluated in Patients Undergoing Bronchoplasty for Lung Cancer?
16:45 - 18:00 | Presenter: Kazunori Hata
- Abstract
Loading... -
+
P2.17-15 - Mediastinoscopic Assessment of N2 Disease and Optimisation of Surgical Treatment of N2 Disease in NSCLC
16:45 - 18:00 | Presenter: George Karimundackal
- Abstract
Loading... -
+
P2.17-16 - Radical en Bloc Resection for Lung Cancer Invading the Spine
16:45 - 18:00 | Presenter: Masato Kato
- Abstract
Loading... -
+
P2.17-17 - Multimodal Treatment in Pathologically Confirmed Single-Station Resectable IIIA-N2 Non-Small Cell Lung Cancer: A Single Center Experience
16:45 - 18:00 | Author(s): L. Tilea
- Abstract
Loading... -
+
P2.17-18 - A Prognostic Score for Patients Receiving Multimodal Treatment for Locally-Advanced Non-Small Cell Lung Cancer
16:45 - 18:00 | Author(s): Julian Taugner
- Abstract
Loading... -
+
P2.17-19 - Concurrent Chemoradiotherapy with Carboplatin-Paclitaxel Versus Cisplatin-Etoposide for Stage III NSCLC Patients – Review of Literature
16:45 - 18:00 | Presenter: Tahir Mehmood
- Abstract
Loading... -
+
P2.17-20 - Systematic Literature Review of Chemoradiotherapy Versus Radiotherapy Alone in Elderly Patients with Stage III Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Tahir Mehmood
- Abstract
Loading... -
+
P2.17-21 - Efficacy of Concurrent Carboplatin-Paclitaxel Chemoradiotherapy with 66 Gy for Elderly Patients with Stage III Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Sachiko Miura
- Abstract
Loading... -
+
P2.17-22 - Cardiac Biomarkers in CART Study (CARdiac Toxicity in Lung Cancer Patients After Chemo-Radiotherapy).
16:45 - 18:00 | Presenter: Nazia Mohammed
- Abstract
Loading... -
+
P2.17-23 - Optimal Therapy of Stage III NSCLC: The Role of Surgery in the Era of Immunotherapy
16:45 - 18:00 | Presenter: Sara Moore
- Abstract
Loading... -
+
P2.17-24 - Does the Change in Body Mass Index During Induction Chemo/Chemoradiotherapy Affect the Outcome of Surgery in Locally Advanced NSCLC?
16:45 - 18:00 | Author(s): Erhan Ozer
- Abstract
Loading... -
+
P2.17-25 - Post-Treatment Neutrophil to Lymphocyte Ratio in Locally Advanced NSCLC Patients Treated with Concurrent Chemoradiotherapy
16:45 - 18:00 | Presenter: Eun Young Park
- Abstract
Loading... -
+
P2.17-26 - Quantifying the Interfractional Motion of the Esophagus During Radiation Therapy for Locally Advanced Non Small Cell Lung Cancer
16:45 - 18:00 | Author(s): Bo Qiu
- Abstract
Loading... -
+
P2.17-27 - IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab + Chemotherapy
16:45 - 18:00 | Presenter: Naiyer A Rizvi
- Abstract
Loading... -
+
P2.17-28 - Real-World Data: Survival Outcomes of Chemotherapy Regimens Given Concurrently with Radiotherapy for Locally Advanced NSCLC
16:45 - 18:00 | Presenter: David Chun Cheong Tsui
- Abstract
Loading... -
+
P2.17-29 - Is Collagen Vascular Disease-Associated Interstitial Lung Disease a High Risk for Lung Cancer Surgery?
16:45 - 18:00 | Presenter: YUKIO Watanabe
- Abstract
Loading... -
+
P2.17-30 - Serum Lipoprotein(A) Correlates with the Effect of Endostar Combined with Concurrent Chemoradiotherapy in Patients with Locally Advanced LSCC
16:45 - 18:00 | Presenter: Haihua Yang
- Abstract
Loading... -
+
P2.17-31 - The Effect of the Extended Bilateral Mediastinal Lymph Node Dissection Through a Median Sternotomy for Non-Small-Cell Carcinoma of the Left Lung.
16:45 - 18:00 | Presenter: Toshiya Yokota
- Abstract
Loading... -
+
P2.17-32 - Dynamic Monitoring Before and After Neo-Adjuvant Crizotinib in Non-Small Cell Lung Cancer: A Brief Report
16:45 - 18:00 | Presenter: Chao Zhang
- Abstract
Loading... -
+
P2.17-33 - Role of Adjuvant Therapy in Pulmonary Adenosquamous Carcinoma
16:45 - 18:00 | Presenter: Jiaxi He
- Abstract
Loading...
-
+
EXH03 - Inivata Exhibit Showcase Session - Liquid Biopsy: Providing Accurate Insights for Advanced NSCLC Patients - A Closer Look at the Validation and Utility of the InVision First - Lung Test (Not IASLC CME Accredited)
- Type: Exhibit Showcase
- Track:
- Presentations: 1
- Coordinates: 9/25/2018, 17:00 - 17:30, Exhibit Showcase Theater
-
+
EXH03.01 - Liquid Biopsy - Providing Accurate Insights for Advanced NSCLC Patients - A Closer Look at the Validation and Utility of the InVision FirstTM - Lung Test
17:00 - 17:30 | Presenter: Ramaswamy Govindan
- Abstract
No abstract available for this presentation
-
+
MTE19 - How I Treat Advanced Stage Thymic Malignancy Patients (Ticketed Session)
- Type: Meet the Expert Session
- Track: Thymoma/Other Thoracic Malignancies
- Presentations: 1
- Coordinates: 9/26/2018, 07:00 - 08:00, Room 205 AC
-
+
MTE19.01 - How I Treat Advanced Stage Thymic Malignancy Patients
07:00 - 08:00 | Presenter: Heather A Wakelee
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MTE20 - Molecular Testing in Small Samples (Ticketed Session)
- Type: Meet the Expert Session
- Track: Pathology
- Presentations: 2
- Coordinates: 9/26/2018, 07:00 - 08:00, Room 202 BD
-
+
MTE20.01 - Molecular Testing in Small Samples
07:00 - 07:30 | Presenter: John W Longshore
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MTE20.02 - Molecular Testing in Small Samples
07:30 - 08:00 | Presenter: Jin-Haeng Chung
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MTE21 - Can I Treat Brain Metastasis with Immunotherapy? (Ticketed Session)
- Type: Meet the Expert Session
- Track: Immunooncology
- Presentations: 2
- Coordinates: 9/26/2018, 07:00 - 08:00, Room 105
-
+
MTE21.01 - Can I Treat Brain Metastasis with Immunotherapy?
07:00 - 07:30 | Presenter: Sarah B Goldberg
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MTE21.02 - Can I Treat Brain Metastasis with Immunotherapy?
07:30 - 08:00 | Presenter: Caroline Chung
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
first
prev
